Mutaflor is a probiotic comprised of a viable non-pathogenic bacteria strain named Escherichia coli Nissle 1917.
The strain was first isolated in Germany by professor Alfred Nissle in the year 1917. Today, the bacteria is grown in fermenters and is placed into enteric-coated gelatine capsules.
Mutaflor has been on the market for almost a century and has been clinically studied for use in a variety of diseases and disorders of the gastrointestinal tract. A number of European studies on E. coli Nissle 1917 have shown positive results when used in conditions such as ulcerative colitis, Crohn’s Disease, chronic constipation, prolonged diarrhea, irritable bowel syndrome and pouchitis.
In Canada, Mutaflor is indicated to normalize stool frequency and consistency in diarrhea and constipation and to reduce abdominal pain and cramping.
Mutaflor from Medical Futures Inc. comes directly from the German manufacturer and is the same strain used in all of the clinical trials. Medical Futures Inc. is the sole authorized distributor for Mutaflor in Canada and in the USA.